Cargando…

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suwaidi, Jassim Al, Salam, Amar M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2001
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59641/ https://www.ncbi.nlm.nih.gov/pubmed/11806792 http://dx.doi.org/10.1186/cvm-2-4-171

Ejemplares similares

Absence of platelet membrane glycoproteins IIb/IIIa from monocytes
Publicado: (1985)

Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
por: Iannetta, Loredana, et al.
Publicado: (2013)

P2Y(12) Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity
por: Berny‐Lang, Michelle A., et al.
Publicado: (2013)

Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins
Publicado: (1990)

The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro(®)) Coated Stent in Patients with Coronary Artery Disease
por: Kim, Weon, et al.
Publicado: (2004)

Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-naïve patients undergoing elective percutaneous coronary intervention
por: Habibi, Zarina, et al.
Publicado: (2023)

Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?
por: Silva, Matthew A, et al.
Publicado: (2006)

Effect of Platelet Glycoprotein IIb/IIIa PLA2 Polymorphism on Severity of Pulmonary Thromboembolism
por: Boroujeni, Hamid Rouhi, et al.
Publicado: (2014)

The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma
por: Kim, Seo-Hee, et al.
Publicado: (2021)

Case-Control Study of Platelet Glycoprotein Receptor Ib and IIb/IIIa Expression in Patients with Acute and Chronic Cerebrovascular Disease
por: Kraft, Peter, et al.
Publicado: (2015)

Detection of High-Risk Atherosclerotic Plaques with Ultrasound Molecular Imaging of Glycoprotein IIb/IIIa Receptor on Activated Platelets
por: Guo, Shengcun, et al.
Publicado: (2015)

Thrombin-induced platelet membrane glycoprotein IIb and IIIa complex formation. An electron microscope study
Publicado: (1981)

Glycoprotein IIb/IIIa and P2Y(12) Induction by Oligochitosan Accelerates Platelet Aggregation
por: Periayah, Mercy Halleluyah, et al.
Publicado: (2014)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
por: Kaluski, Edo
Publicado: (2008)

A prospective analysis of complications related to the use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
por: Rocha, RM, et al.
Publicado: (2001)

Relationship of Platelet Glycoprotein IIb/IIIa and CD62P With Hypercoagulable State After Oncologic Surgery
por: Zhong, Xin, et al.
Publicado: (2020)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis
por: Li, Jiabei, et al.
Publicado: (2015)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Effects of glycoprotein IIb/IIIa receptor blocker (tirofiban) in acute coronary syndromes angiographic, scintigraphic and molecular biology studies
por: Rizk, A, et al.
Publicado: (2001)

An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel
por: Joo, Seung-Jae, et al.
Publicado: (2015)

Evidence that activation of platelet calpain is induced as a consequence of binding of adhesive ligand to the integrin, glycoprotein IIb-IIIa
Publicado: (1993)

The Inhibitory Effects of Protaetia brevitarsis seulensis Larvae Extract on Human Platelet Aggregation and Glycoprotein IIb/IIIa Expression
por: Kwon, Hyuk-Woo, et al.
Publicado: (2023)

Influence of glycoprotein IIb/IIIa inhibitors on bleeding events after successful resuscitation and percutaneous coronary intervention
por: Biever, Paul Marc, et al.
Publicado: (2019)

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)

Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021)

The platelet glycoprotein IIb/IIIa-like protein in human endothelial cells promotes adhesion but not initial attachment to extracellular matrix
Publicado: (1987)

Visualization of Activated Platelets by Targeted Magnetic Resonance Imaging Utilizing Conformation-Specific Antibodies against Glycoprotein IIb/IIIa
por: von zur Muhlen, Constantin, et al.
Publicado: (2009)

Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
por: Sim, Doo Sun, et al.
Publicado: (2003)

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant
por: Deng, Qiao, et al.
Publicado: (2020)

Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
por: Hekmat, Hamidreza, et al.
Publicado: (2022)

Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis
por: Al-Ali, Amein, et al.
Publicado: (2008)

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction
por: Howard, J. P., et al.
Publicado: (2014)

Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis
por: Zhu, Xiaolin, et al.
Publicado: (2020)

Intra-Arterial Glycoprotein IIb/IIIa Inhibitor Treatment for Symptomatic Intracranial Atherosclerotic Stenosis Presenting as Large Vessel Occlusions
por: Srivatsan, Aditya, et al.
Publicado: (2020)

Synthesis by cultured human umbilical vein endothelial cells of two proteins structurally and immunologically related to platelet membrane glycoproteins IIb and IIIa
Publicado: (1986)

Receptor GP IIb/IIIa as an Indicator of Risk in Vascular Events
por: Fiodorenko-Dumas, Żanna, et al.
Publicado: (2019)

Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics
por: Bauer, Timm, et al.
Publicado: (2010)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
por: Choi, Woong Gil, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pet194meh6sgc40aqud253hvhn